Literature DB >> 24857020

Distinct tau prion strains propagate in cells and mice and define different tauopathies.

David W Sanders1, Sarah K Kaufman1, Sarah L DeVos1, Apurwa M Sharma1, Hilda Mirbaha1, Aimin Li1, Scarlett J Barker1, Alex C Foley2, Julian R Thorpe2, Louise C Serpell2, Timothy M Miller1, Lea T Grinberg3, William W Seeley3, Marc I Diamond4.   

Abstract

Prion-like propagation of tau aggregation might underlie the stereotyped progression of neurodegenerative tauopathies. True prions stably maintain unique conformations ("strains") in vivo that link structure to patterns of pathology. We now find that tau meets this criterion. Stably expressed tau repeat domain indefinitely propagates distinct amyloid conformations in a clonal fashion in culture. Reintroduction of tau from these lines into naive cells reestablishes identical clones. We produced two strains in vitro that induce distinct pathologies in vivo as determined by successive inoculations into three generations of transgenic mice. Immunopurified tau from these mice recreates the original strains in culture. We used the cell system to isolate tau strains from 29 patients with 5 different tauopathies, finding that different diseases are associated with different sets of strains. Tau thus demonstrates essential characteristics of a prion. This might explain the phenotypic diversity of tauopathies and could enable more effective diagnosis and therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24857020      PMCID: PMC4171396          DOI: 10.1016/j.neuron.2014.04.047

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  68 in total

1.  A yeast prion provides a mechanism for genetic variation and phenotypic diversity.

Authors:  H L True; S L Lindquist
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

Review 2.  The transcellular spread of cytosolic amyloids, prions, and prionoids.

Authors:  Adriano Aguzzi; Lawrence Rajendran
Journal:  Neuron       Date:  2009-12-24       Impact factor: 17.173

3.  Predicting regional neurodegeneration from the healthy brain functional connectome.

Authors:  Juan Zhou; Efstathios D Gennatas; Joel H Kramer; Bruce L Miller; William W Seeley
Journal:  Neuron       Date:  2012-03-21       Impact factor: 17.173

Review 4.  Neuropathology underlying clinical variability in patients with synucleinopathies.

Authors:  Glenda M Halliday; Janice L Holton; Tamas Revesz; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2011-07-01       Impact factor: 17.088

5.  Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes.

Authors:  Giuseppe Legname; Hoang-Oanh B Nguyen; David Peretz; Fred E Cohen; Stephen J DeArmond; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

6.  Initiation and synergistic fibrillization of tau and alpha-synuclein.

Authors:  Benoit I Giasson; Mark S Forman; Makoto Higuchi; Lawrence I Golbe; Charles L Graves; Paul T Kotzbauer; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2003-04-25       Impact factor: 47.728

7.  Real-time imaging of beta-catenin dynamics in cells and living mice.

Authors:  Snehal Naik; David Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

Review 8.  Classification and basic pathology of Alzheimer disease.

Authors:  Charles Duyckaerts; Benoît Delatour; Marie-Claude Potier
Journal:  Acta Neuropathol       Date:  2009-04-21       Impact factor: 17.088

Review 9.  Neuroimaging insights into network-based neurodegeneration.

Authors:  Michael D Greicius; Daniel L Kimmel
Journal:  Curr Opin Neurol       Date:  2012-12       Impact factor: 5.710

10.  Direct intraventricular delivery of drugs to the rodent central nervous system.

Authors:  Sarah L DeVos; Timothy M Miller
Journal:  J Vis Exp       Date:  2013-05-12       Impact factor: 1.355

View more
  393 in total

1.  Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.

Authors:  Santiago V Salazar; Timothy O Cox; Suho Lee; A Harrison Brody; Annabel S Chyung; Laura T Haas; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2018-12-05       Impact factor: 6.167

Review 2.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

3.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

4.  A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick Disease.

Authors:  Pawel Tacik; Michael DeTure; Kelly M Hinkle; Wen-Lang Lin; Monica Sanchez-Contreras; Yari Carlomagno; Otto Pedraza; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

5.  Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.

Authors:  Jon B Toledo; Pallavi Gopal; Kevin Raible; David J Irwin; Johannes Brettschneider; Samantha Sedor; Kayla Waits; Susana Boluda; Murray Grossman; Vivianna M Van Deerlin; Edward B Lee; Steven E Arnold; John E Duda; Howard Hurtig; Virginia M-Y Lee; Charles H Adler; Thomas G Beach; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2015-12-31       Impact factor: 17.088

6.  Crystal Structures of IAPP Amyloidogenic Segments Reveal a Novel Packing Motif of Out-of-Register Beta Sheets.

Authors:  Angela B Soriaga; Smriti Sangwan; Ramsay Macdonald; Michael R Sawaya; David Eisenberg
Journal:  J Phys Chem B       Date:  2016-01-11       Impact factor: 2.991

7.  Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Authors:  Maiko Ono; Naruhiko Sahara; Katsushi Kumata; Bin Ji; Ruiqing Ni; Shunsuke Koga; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Mari Yoshida; Isao Hozumi; Yasumasa Yoshiyama; John C van Swieten; Agneta Nordberg; Tetsuya Suhara; Ming-Rong Zhang; Makoto Higuchi
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

8.  Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus α-synuclein and β-amyloid aggregates.

Authors:  Barbara E Stopschinski; Brandon B Holmes; Gregory M Miller; Victor A Manon; Jaime Vaquer-Alicea; William L Prueitt; Linda C Hsieh-Wilson; Marc I Diamond
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

10.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.